Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Goodwill: 2014-2023

Historic Goodwill for Coherus Oncology (CHRS) over the last 7 years, with Dec 2023 value amounting to $943,000.

  • Coherus Oncology's Goodwill changed negligibly% to $943,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $943,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $943,000 for FY2023, which is negligibly% changed negligibly from last year.
  • Coherus Oncology's Goodwill amounted to $943,000 in Q4 2023, which was down 0.00% from $943,000 recorded in Q3 2023.
  • Coherus Oncology's 5-year Goodwill high stood at $943,000 for Q1 2019, and its period low was $900,000 during Q4 2021.
  • Its 3-year average for Goodwill is $936,857, with a median of $943,000 in 2023.
  • In the last 5 years, Coherus Oncology's Goodwill dropped by 4.56% in 2021 and then increased by 4.78% in 2022.
  • Coherus Oncology's Goodwill (Quarterly) stood at $943,000 in 2019, then remained steady at $943,000 in 2020, then dropped by 4.56% to $900,000 in 2021, then grew by 4.78% to $943,000 in 2022, then remained steady at $943,000 in 2023.
  • Its last three reported values are $943,000 in Q4 2023, $943,000 for Q3 2023, and $943,000 during Q4 2022.